Skip to content
drillr.ai
Sign up

AZNVD

AstraZeneca PLC

Healthcare · Drug Manufacturers - General · GB

Also listed · AZN →AZN.CA →AZNVF →MILE.CA →OJO.CA →
—
Ask drillr

  • Sep 15, 2026, 10:41 UTC

    Zacks added Aptiv, AstraZeneca and Bank OZK to its Zacks Rank #5 (Strong Sell) list on September 15, 2026.

    Source:

  • Sep 14, 2026, 09:15 UTC

    Eris Lifesciences elevated Sanjeev Mehra to Vice President – Human Resources & Organisational Development in April 2026.

    Source:

  • Sep 11, 2026, 03:55 UTC

    In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

    Source:

  • Sep 9, 2026, 00:20 UTC

    On the fifth and final day of the 2026 national medical insurance drug list negotiations, price consultations for the commercial insurance innovative drug catalog began, with multiple pharmaceutical companies including AstraZeneca, Sanofi, and subsidiaries of Kechi Life and Hengrundasheng entering the venue.

    Source:

  • Sep 8, 2026, 11:45 UTC

    AstraZeneca announced that in the TITANIA study, Tozorakimab 300mg reduced the risk of moderate-to-severe exacerbations by 29% in the overall COPD patient population who are current or former smokers.

    Source:

  • Sep 8, 2026, 06:20 UTC

    China's Ministry of Commerce added 84 new key foreign-invested projects, including six landmark projects such as Fujian Benz Phase II and AstraZeneca's global strategic R&D center, with total investment of $19.46 billion.

    Source:

  • Sep 1, 2026, 06:05 UTC

    AstraZeneca completed its acquisition agreement for ZEGFROVY.

    Source:

  • Aug 28, 2026, 09:23 UTC

    AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.

    Source:

  • Aug 27, 2026, 06:00 UTC

    Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE (tezepelumab-ekko) in patients with eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints through week 52.

    Source:

  • Aug 26, 2026, 03:20 UTC

    Sinopharm Holding and AstraZeneca launched a special cooperation project on essential medicines in Shanghai, deepening their strategic partnership in pharmaceutical distribution and grassroots healthcare accessibility.

    Source:

  • Aug 25, 2026, 06:52 UTC

    AstraZeneca PLC priced a €2.55 billion euro bond offering across four tranches, issued by its subsidiary AstraZeneca Finance LLC with a parent guarantee, for general corporate purposes.

    Source:

  • Aug 20, 2026, 10:04 UTC

    Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.

    Source:

  • Aug 20, 2026, 08:55 UTC

    AstraZeneca's Ravulizumab received approval in China for a third indication, treating paroxysmal nocturnal hemoglobinuria (PNH), as shown on the NMPA website.

    Source:

  • Aug 18, 2026, 12:23 UTC

    On August 18, 2026, Yingte Group and Hangzhou PICC signed a strategic cooperation agreement to jointly launch a provincial exclusive specialty drug commercial insurance product called 'Yingte-PICC Yao Kangbao'.

    Source:

  • Aug 17, 2026, 22:00 UTC

    The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.

    Source:

  • Aug 17, 2026, 13:22 UTC

    AstraZeneca discontinued a late-stage trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer patients lacking PD-L1, following a data monitoring committee recommendation.

    Source:

  • Aug 17, 2026, 06:28 UTC

    AstraZeneca announced on Monday that it is discontinuing a late-stage trial testing volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer.

    Source:

  • Aug 17, 2026, 06:19 UTC

    AstraZeneca announced the official launch of Tezspire (tezepelumab) in China on August 17, 2026.

    Source:

  • Aug 10, 2026, 15:00 UTC

    A London-based drugmaker (AstraZeneca) announced plans to invest US$30 billion in U.S. research and development and supply chain infrastructure over five years.

    Source:

  • Aug 5, 2026, 23:01 UTC

    The UK government expanded its fast-track research visa program, allowing over 100 UK companies including AstraZeneca and Jaguar Land Rover to bring in workers, aiming to capitalize on US President Donald Trump's immigration crackdown.

    Source:

  • Aug 5, 2026, 14:01 UTC

    AstraZeneca shares rose about 6% on Wednesday after Reuters reported there are no merger discussions with Bristol Myers Squibb, easing investor concerns.

    Source:

  • Aug 2, 2026, 19:36 UTC

    AstraZeneca has held talks with Bristol Myers Squibb about a potential merger, as reported by the Financial Times on Sunday.

    Source:
← PreviousPage 3Next →